24207-22-5

Usage

Chemical Properties

White solid

InChI:InChI=1/C7H8BrNO/c1-5-3-4-6(10-2)7(8)9-5/h3-4H,1-2H3

Upstream product

• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 23003-35-2 2-bromo-3-hydroxy-6-methylpyridine 
• 74-88-4 methyl iodide 

Downstream Products

• 54232-43-8 6-bromo-5-methoxy-2-pyridinecarboxylic acid 
• 1450923-69-9 C₂₆H₂₆N₄O₅S₂ 
• 329217-74-5 6-bromo-5-methoxypicolinaldehyde 
• 178876-92-1 6-Bromo-5-hydroxy-pyridine-2-carboxylic acid 
• 170235-18-4 methyl 2-bromo-3-methoxy-6-pyridinecarboxylic acid 
• 170235-19-5 methyl 2-bromo-3-hydroxy-6-pyridinecarboxylate 
• 1610625-66-5 N,N''-bis[1-benzyloxy-2-oxo-3-[(carboxyamidomethyl)oxy]-6-carbonyl(2-mercaptothiazolide)pyridine]-N'-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-bis(2-aminoethyl)amine 
• 1610625-65-4 N,N''-bis[1-benzyloxy-2-oxo-3-[(carboxyamidomethyl)oxy]-6-(methoxycarbonyl)pyridine]-N'-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-bis(2-aminoethyl)amine 
• 1610625-64-3 1-benzyloxy-2-oxo-3-[(carboxymethyl)oxy]-6-pyridinecarboxylic acid 6-methyl ester 
• 1610625-63-2 1-benzyloxy-2-oxo-3-[(carboxymethyl)oxy]-6-pyridinecarboxylic acid dimethyl ester 

Relevant academic research and scientific papers

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

COMPOSITIONS AND USES OF AMIDINE DERIVATIVES

Use of a compound of formula (I): wherein A, X, Y, R1 and R2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-solvent, is also disclosed.

DI-MACROCYCLES

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia

The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1

Heterocyclic derivatives for the treatment of diabetes and other diseases

The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.

Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors

Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the

Total synthesis of dimethyl sulfomycinamate

Dimethyl sulfomycinamate (1), a methanolysis product from the natural antibiotic sulfomycin I, is synthesized in 11 steps. The chemistry of various pyridine, thiazole, and oxazole heterocycles and their coupling reactions under palladium catalysis are examined. The key transformations in the synthesis are the selective palladium-catalyzed coupling reactions on doubly activated pyridine 62 and the condensation reaction between bromo ketone 69 and amide 28 to form the oxazole moiety 76. The first preparation of oxazole triflates is described, as are some of their chemical properties.

Total synthesis of dimethyl sulfomycinamate

The first total synthesis of dimethyl sulfomycinamate (1) is described. Highlights of the synthesis include a selective palladium-catalyzed coupling reaction on the bromotriflate 21, and a condensation reaction to form the oxazole ring.